Natera Medical (NTRA) Amount of Cash per Share

Natera, Inc. (NTRA) is based on unique genomic data and proprietary DNA analysis. The estimated cash per share demonstrates current liquidity, with the value of 7.63 characterizing this level. Management's aggressive strategy ensures rapid revenue growth, while the focus on in-house R&D and patent protection eliminates the need for mergers with other players.
Analytical breakdowns for Natera, Inc.
- market price and analyst price targets:
- market capitalization details:
- balance sheet net asset value indicators:
- debt and solvency information:
- net income and valuation ratios data:
NTRA - Net Income|Future Net Profit Natera, Inc.|NTRA - Price to Earnings Ratio|Future Price to Earnings Multiple Natera, Inc.|NTRA - PEG Multiple|EV/EBITDA Multiple Natera Corp|NTRA - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Natera|NTRA - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months natera.com|NTRA - Earnings per share growth in current year|Net earnings per share change forecast for next year Natera, Inc.
- issuer revenue and sales details:
- margin level information:
- cash position and cash flow details:
Summary company analysis:NTRA Natera, Inc.

This indicator determines the volume of liquid assets per common share, allowing for an assessment of the internal capital cushion and investor protection. Analyzing the average cash per share reveals how explosive demand for Natera, Inc. (NTRA) oncology tests has transitioned the company from depleting reserves to self-funding via positive operating cash flow.